Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Innovation Pharmaceuticals Inc (EM) IPIX

Healthcare Biotechnology
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.


EXPM:IPIX - Post by User

Innovation Pharmaceuticals Inc (EM)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
  • kaos12X
Post by kaos12on May 21, 2020 12:25pm
242 Views
Post# 31056679

Today’s PR

Today’s PRToday's news release is awesome news!  It also calls out Gilead's Remdesivir as inferior to Brilacidin as it KILLS the virus. Also foreshadowing multiple news releases in the next two weeks. Would be nice if SH could keep up to news releases. Still haven't posted today's release as I type this. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities